John P. Sharp

VP Finance, Sequenom.

Companies

Skye Bioscience, Inc.Chief financial officer Apr 28, 2026 to now¹
PhaseBio Pharmaceuticals IncChief financial officer Oct 17, 2018 to May 24, 2022²
LIGAND PHARMACEUTICALS INCChief financial officer May 2, 2007 to Feb 14, 2014³
SequenomVP Finance Jun 8, 2006 to Jan 22, 2007⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

PhaseBio Pharmaceuticals Inc65,767 shares⁵May 20, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

May 20, 2022Granted 6,026 shares at $0.68 of PhaseBio Pharmaceuticals Inc⁵
Nov 19, 2021Granted 2,017 shares at $2.01 of PhaseBio Pharmaceuticals Inc⁶
Nov 3, 2021Exercised options 7,500 shares at $1.68 of PhaseBio Pharmaceuticals Inc⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSkye Bioscience, Inc., Chief financial officer
2
SEC EDGARPhaseBio Pharmaceuticals Inc, Chief financial officer
3
SEC EDGARLIGAND PHARMACEUTICALS INC, Chief financial officer
4
SEC EDGARSequenom, VP Finance
5
SEC EDGARPhaseBio Pharmaceuticals Inc shares after the filing of May 20, 2022
6
SEC EDGARForm 4 filed Nov 23, 2021
7
SEC EDGARForm 4 filed Nov 3, 2021